Featured Research

from universities, journals, and other organizations

Effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic

Date:
March 1, 2011
Source:
Public Library of Science
Summary:
A new study makes the case that a combination of methadone substitution therapy and anti-retroviral treatment would have the greatest effect on reducing new infections and improving quality of life in a region where HIV is spreading rapidly among intravenous drug users.

A new study from Stanford researchers published in PLoS Medicine makes the case that a combination of methadone substitution therapy and anti-retroviral treatment would have the greatest effect on reducing new infections and improving quality of life in a region where HIV is spreading rapidly among intravenous drug users.

In the past decade, an epidemic of HIV has swept through Ukraine, fueled mostly by intravenous drug use. Of Ukraine's approximately 390,000 intravenous drug users as many as half are HIV-infected. Researchers at Stanford and Veterans Affairs Palo Alto Health Care System have demonstrated, using a cost-effectiveness modeling study, that the most effective way to combat the spreading disease is a combined program of drug substitution -- providing methadone for opiate users, for instance -- and anti-retroviral therapy for those already infected with HIV.

"HIV is spreading in Eastern Europe more quickly than in any other part of the world," said Margaret Brandeau, the Coleman F. Fung Professor of Engineering at Stanford University and senior author of the study. "Our study shows that substitution therapy for injection drug users is an inexpensive and effective means of curbing HIV transmission in the region."

With no further intervention, the study predicts that HIV prevalence will reach 67.2 percent in intravenous drug users in 20 years. The authors further show that providing drug-substitution to just 25 percent of intravenous drug users today could lower that figure considerably.

"Not only does drug substitution therapy work, but it is remarkably cost-effective when you consider total costs of treating and caring for a growing HIV-infected community," said lead author Sabina Alistar.

"Providing effective drug substitution therapy and HIV antiretroviral therapy together to the injection-drug-using community protects the entire population -- it actually prevents more infections in non-drug users than in the drug-using community," said Douglas K. Owens, co-author and a senior investigator at the VA Palo Alto Health Care System and professor of medicine at Stanford University.

This research was supported by Grant Number R01DA15612 from the National Institute on Drug Abuse. Sabina S. Alistar is also supported by a Stanford Graduate Fellowship. Dr. Owens is supported by the Department of Veterans Affairs.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alistar SS, Owens DK, Brandeau ML (2011). Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine. PLoS Med, 8(3): e1000423 DOI: 10.1371/journal.pmed.1000423

Cite This Page:

Public Library of Science. "Effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic." ScienceDaily. ScienceDaily, 1 March 2011. <www.sciencedaily.com/releases/2011/03/110301184045.htm>.
Public Library of Science. (2011, March 1). Effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/03/110301184045.htm
Public Library of Science. "Effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic." ScienceDaily. www.sciencedaily.com/releases/2011/03/110301184045.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins